For a cosmetic injector, the cheaper vial bought online can turn out to be the most expensive purchase of their career.
The Therapeutic Goods Administration (TGA) has warned that counterfeit Botox vials are still arriving in Australia, despite an earlier alert issued in July 2025. According to the regulator, the fake products were packaged to look like genuine Allergan stock and were bought from overseas websites rather than through Australian pharmacies.
For patients, the risk is a dangerous product. For registered practitioners and clinic owners, the risk runs further. A single overseas order can lead to fines, a criminal record and action against their registration, often all at once.
Why cosmetic injectables are so tightly controlled
To understand that exposure, it helps to start with how these products are classified. Botulinum toxin is a prescription-only medicine in Australia, generally regulated as a Schedule 4 substance. Dermal fillers and the enzymes used to dissolve them are also regulated therapeutic goods.
The TGA is clear about who may bring these products into the country. Only the approved sponsor listed on the Australian Register of Therapeutic Goods (ARTG), or its authorised agent, can lawfully import cosmetic injectables for commercial supply. Anything sourced outside that chain is either a parallel import or a counterfeit.
Neither is a safe shortcut. The regulator has linked parallel imports to poor cold-chain storage and, in some cases, to acquired botulism after cosmetic procedures. Counterfeits carry an even greater risk, because no one can say with confidence what is inside the vial.
Legal exposure one: the TGA
The first and most common consequence comes from the TGA itself. Under the Therapeutic Goods Act 1989, the regulator can issue infringement notices for unlawfully importing therapeutic goods and for advertising prescription-only medicines to the public.
Recent enforcement shows how often this is happening. In 2026, the TGA fined a Queensland-based individual for allegedly importing counterfeit botulinum toxin and promoting prescription-only injectables on social media. In May 2026, a Victorian nurse and another individual paid infringement notices totalling $19,800 over the alleged importation of unapproved pre-filled syringes. The TGA’s published list of enforcement actions now includes a long run of notices issued to AHPRA-registered practitioners in Victoria and New South Wales.
The products themselves are rarely recovered. Under instruction from the TGA, the Australian Border Force can seize and destroy unlawful imports at the border. The regulator has also named unapproved goods used in cosmetic procedures as a compliance priority for 2026 and 2027, which means more scrutiny, not less.
Legal exposure two: when it becomes a criminal matter
An infringement notice can feel like the end of the matter, but it is not always where things stop. When notices go unpaid or the conduct is serious, the TGA can move to prosecution.
That is exactly what happened to one Melbourne woman, who was convicted by the Magistrates’ Court of Victoria on three charges of unlawfully importing therapeutic goods, including pre-filled dermal filler syringes. The prosecution followed earlier infringement notices that had not been paid. The TGA has stated plainly that knowingly importing, supplying or giving away counterfeit therapeutic goods is illegal, and related conduct such as forging prescriptions is a criminal offence in its own right.
The broader climate is also hardening. The TGA recently took part in a coordinated international operation against illicit and counterfeit medicines that led to more than 260 arrests and the dismantling of over 60 criminal groups.
A conviction does not end in the courtroom. It can affect travel, future employment and, for a registered practitioner, the right to keep practising. At this stage, early advice from criminal law specialists before responding to the regulator can shape the entire outcome, from whether charges proceed to how a matter is resolved.
Legal exposure three: AHPRA and your registration
For nurses, doctors and dentists, the consequences can also reach their professional standing. The TGA has said it may refer registered health practitioners to AHPRA and the relevant National Board when it finds unlawful importation.
Once a matter reaches AHPRA, the outcomes range from cautions and conditions to suspension or a ban on practising. In one Queensland case, a nurse was banned from nursing for two years after AHPRA found she had injected botulinum toxin without a prescription, created false treatment records and given misleading information to investigators. The ban also prevented her from providing any health service, including cosmetic injectables, until she is re-registered.
That case shows how a disciplinary matter can grow. The original conduct was serious, but the false records and misleading answers made the outcome considerably worse.
Why the stakes are higher now
These risks sit alongside a much stricter rulebook than the industry had only a few years ago. Since AHPRA’s new guidelines for non-surgical cosmetic procedures took effect in September 2025, several obligations have tightened.
- Botulinum toxin can only be prescribed after a consultation, and practitioners must assess a patient’s physical and psychological suitability for treatment.
- Nurses must complete at least 12 months of full-time clinical practice before expanding their scope to include cosmetic injectables.
- Advertising must name the registered practitioner performing the procedure, influencer testimonials are prohibited, and ads must not target people under 18.
Taken together, these changes mean regulators now have clearer standards to measure practitioners against, and fewer grey areas to work within.
Practical steps for practitioners and clinic owners
With clearer standards in place, the best protection is a set of simple habits applied every time stock is ordered or a treatment is booked.
- Buy through the proper chain. Source products only from ARTG-listed sponsors or authorised Australian wholesalers, never from overseas websites or social media sellers.
- Check batch numbers. Compare stock against the TGA’s safety alerts, which list counterfeit batch numbers that should not be used.
- Keep records accurate. Prescriptions, consultations and stock records should be complete and truthful. As the Queensland case shows, poor records can turn one problem into several.
- Get advice before you respond. If a TGA notice, Border Force letter or AHPRA notification arrives, speak to a lawyer before replying. What you say early can be used later.
None of these steps is complicated, yet each one closes off a common path into regulatory or criminal trouble.
A word to patients
The same rules that protect practitioners also give patients a straightforward way to protect themselves. For anyone considering anti-wrinkle injections or fillers, the safest choice is a registered cosmetic and skin clinic that can confirm the product is ARTG-approved and name the practitioner who will treat you.
Patients can check a practitioner’s registration on the AHPRA public register before booking. Anyone who suspects a counterfeit or unapproved product can report it to the TGA. Unusually cheap treatments, products bought online or providers who cannot name the medicine they are using are all reasons to look elsewhere.
Early advice makes the difference
Counterfeit and unapproved injectables are no longer a fringe problem, and regulators are treating them that way. For practitioners, the legal consequences rarely arrive one at a time. A TGA fine can lead to a prosecution, and either can trigger an AHPRA investigation.
The earlier you seek advice, the more options you have. If you have received a notice from the TGA, been contacted by Border Force or been notified by AHPRA, Gallant Law offers a free and confidential consultation to help you understand where you stand and what to do next.
